---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-063059"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-05-18T13:01:28+00:00"
generated_at: "2026-05-18T13:02:56.643202+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MetaVia announces three late-breaking abstracts accepted for ADA 2026 poster presentations

## Summary
- DA-1726 (GLP-1/glucagon dual agonist) Phase 1 Part 3 titration study data expected Q4 2026.
- Vanoglipel (GPR119 agonist) preclinical combo data with resmetirom for MASH and metformin for T2D.
- Presentations at ADA 2026 in New Orleans, June 5-8; posters available after event.
- CEO notes DA-1726 potential as differentiated obesity treatment; vanoglipel broad liver/metabolic therapeutic potential.

## SEC filing metadata
- accession: 0001104659-26-063059
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-05-18T13:01:28+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926063059/0001104659-26-063059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926063059/mtva-20260518x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-063059
- JSON: https://secwatch.observer/filing/0001104659-26-063059.json
- Plain text: https://secwatch.observer/filing/0001104659-26-063059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.